UnknownNot Applicable

Exercise Pressor Reflex and Lifelong Training

Italy48 participantsStarted 2019-08-01

Plain-language summary

Cardiovascular diseases represent the first mortality cause in the world. Ageing is considered as the most prominent risk factor for this kind of diseases. Also, hypertension represents one of the modifiable risk factors. Blood pressure response to exercise is governed by three systems: central command, baroreflex, and a feedback mechanism originating in the skeletal muscle. An abnormal cardiovascular response to exercise facilitates the occurrence of cardiovascular events. The goal of the study is to characterize the cardiovascular response in lifelong trained individuals and explore the potential benefits of endurance and strength training on cardiovascular regulation to exercise onset.

Who can participate

Age range

18 Years – 75 Years

Sex

MALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria General: * Young: 18 - 30, males, non smokers * Old Sedentary: 65 -75, males, non smokers * Old Endurance Trained: 65 -75, males, non smokers * Old Strength Trained: 65 - 75, males, non smokers Exercise history (different for each group): * Young: ≤ 5 h/week * Old Sedentary: ≤ 2h/week * Old Endurance Trained: ≥ 5 h/week, ≥ 30 years of practice, ≥ 4 sessions/week * Old Strength Trained: ≥ 5 h/week, ≥ 30 years of practice, ≥ 4 sessions/week Exclusion Criteria: * History of cardiovascular events/diseases * Respiratory, musculoskeletal, renal, and insulin-resistant diseases * Hypercholesterolemia * Use of beta-blockers * BMI ≥ 30

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Mean Arterial Blood Pressure (MAP)

Timeframe: 1 week after recruitment of the subject - We will measure the changes from baseline to the steady state response ( average of 3rd minute)

Heart Rate (HR)

Timeframe: 1 week after recruitment of the subject - We will measure the change from baseline to peak (peak response in HR due to PLM)

Muscle Sympathetic Nerve Activity - Microneurography

Timeframe: 1 week after recruitment - We will measure the change from baseline to mean value (during stimulation)

Trial details

NCT IDNCT04013022

SponsorUniversita di Verona

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-11-29

Contact for this trial

Massimo Venturelli, PhD

+39 0458425114 massimo.venturelli@univr.it

View on ClinicalTrials.gov More Healthy Aging trials